Table 1

Clinical Characteristics and Treatment at Baseline

Whole Cohort (N = 646)LTPR (n = 306)Non-LTPR (n = 340)p Value
Male532 (82)247 (81)285 (84)0.18
Age, yrs60.1 ± 10.260.9 ± 10.359.3 ± 10.10.05
BMI, kg/m227.2 ± 4.526.3 ± 4.028.0 ± 4.7<0.01
Medical history
 Hypertension313 (49)148 (48)165 (49)0.52
 Type II diabetes177 (27)68 (22)109 (32)<0.01
 Dyslipidemia283 (44)137 (45)146 (43)0.35
 Current smoker286 (44)126 (41)160 (47)0.08
 Previous CAD197 (31)89 (29)108 (32)0.26
Treatment
 Beta-blocker445 (69)221 (72)224 (66)0.05
 RAS inhibitor486 (75)224 (73)262 (77)0.21
 Statin614 (95)292 (95)322 (95)0.41
 PPI639 (99)303 (99)336 (99)0.81
Antiplatelet agent<0.01
 Ticagrelor276 (43)167 (55)109 (32)
 Prasugrel370 (57)139 (45)231 (68)
Presentation0.97
 STEMI258 (40)122 (40)136 (40)
 UA or NSTEMI388 (60)184 (60)204 (60)
 EF, %56.4 ± 7.755.8 ± 8.457.0 ± 6.90.04
Biological parameters
 CRP, mg/l4.6 ± 13.75.0 ± 18.74.1 ± 6.70.43
 Platelets, g/l236.2 ± 68.5240.0 ± 79.8233.0 ± 56.40.19
 Triglycerides, g/l1.4 ± 1.11.3 ± 1.31.4 ± 0.90.39
 Cholesterol, g/l1.5 ± 0.41.5 ± 0.51.5 ± 0.40.80
 HDL, g/l0.5 ± 0.10.5 ± 0.10.4 ± 0.1<0.01
 LDL, g/l0.8 ± 0.30.8 ± 0.40.8 ± 0.30.59
 Creatinine, μmol/l91.2 ± 50.991.1 ± 34.191.4 ± 62.30.95
 LTPR305 (47)151 (47)154 (48)
Access site0.63
 Femoral28 (4)12 (4)16 (5)
 Radial618 (96)294 (96)324 (95)
Number of vessels treated0.09
 1548 (85)262 (86)286 (84)
 284 (13)34 (11)50 (15)
 314 (2)10 (3)4 (1)
Stent type0.85
 DES585 (91)277 (91)308 (91)
 BVS21 (3)10 (3)11 (3)
 BMS24 (4)10 (3)14 (4)
 None16 (3)9 (3)7 (2)

Values are n (%) or mean ± SD.

BMI = body mass index; BMS = bare-metal stent(s); BVS = bioresorbable vascular scaffold; CAD = coronary artery disease; DES = drug-eluting stent(s); EF = ejection fraction; HDL = high-density lipoprotein; LDL = low-density lipoprotein; LTPR = low on-treatment platelet reactivity; RAS = renin-angiotensin system; PPI = proton pump inhibitors; STEMI = ST-segment elevation myocardial infarction; NSTEMI = non–ST-segment elevation myocardial infarction; UA = unstable angina.